Shares of Pain Therapeutics (NASDAQ:PTIE) fell 1.2% during mid-day trading on Tuesday . The company traded as low as $2.36 and last traded at $2.42, with a volume of 103,615 shares traded. The stock had previously closed at $2.45.

Separately, Zacks Investment Research lowered shares of Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th.

The company’s market capitalization is $110.74 million. The stock has a 50 day moving average price of $2.48 and a 200-day moving average price of $2.24.

Pain Therapeutics (NASDAQ:PTIE) last released its quarterly earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.07. On average, equities research analysts anticipate that Pain Therapeutics will post ($0.42) EPS for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.